Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | MC4R | P32245 | 3/20 | 0.53 |
| ▸ | MC5R | P33032 | 3/20 | 0.53 |
| ▸ | MC3R | P41968 | 2/20 | 0.53 |
| ▸ | MC1R | Q01726 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23710478 | 0.93 | SIGMAR1 (0.53) | SIGMAR1CYP1A2CYP2A6MC4RMC5R | |
| SCHEMBL21447597 | 0.89 | CYP1A2 (0.57) | SIGMAR1CYP1A2CYP2A6MC4RMC5R | |
| SCHEMBL9373302 | 0.84 | SIGMAR1 (0.68) | SIGMAR1CYP1A2MC4RMC5RMC3R | |
| SCHEMBL9666471 | 0.82 | SIGMAR1 (0.59) | SIGMAR1CYP1A2CYP2A6MC4RMC5R | |
| SCHEMBL23330225 | 0.82 | SIGMAR1 (0.59) | SIGMAR1CYP1A2CYP2A6MC4RMC5R | |
| SCHEMBL8091487 | 0.81 | SIGMAR1 (0.70) | SIGMAR1 | |
| SCHEMBL597668 | 0.80 | SIGMAR1 (0.65) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL29663820 | 0.80 | SIGMAR1 (0.65) | SIGMAR1CYP1A2CYP2A6HDAC1HDAC8 | |
| SCHEMBL140016 | 0.79 | CYP1A2 (0.68) | SIGMAR1CYP1A2CYP2A6BCHE | |
| SCHEMBL30418669 | 0.79 | SIGMAR1 (0.68) | SIGMAR1CYP1A2CYP2A6MC4RMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | DCLRE1A, AZI2, CHD9 | SIGMAR1 4822/4885CYP1A2 1525/4885CYP2A6 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.